Literature DB >> 12366391

Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine.

Thiruma V Arumugam1, Ian A Shiels, Solomon B Margolin, Stephen M Taylor, Lindsay Brown.   

Abstract

1. Pirfenidone, an antifibrotic compound with anti-inflammatory effects, has been investigated in a rat model of acute experimental ischaemia-reperfusion injury of the small intestine. 2. Occlusion of the superior mesenteric artery in young adult female rats for 30 min followed by reperfusion for 120 min induced significant local and systemic effects, including tissue haemorrhage with oedema, elevated serum concentrations of tumour necrosis factor (TNF)-alpha, neutropenia, hypotension and bradycardia. 3. Administration of pirfenidone (200 mg/kg, p.o., i.v. or i.p.) 30 min before occlusion completely inhibited the increase in serum TNF-alpha concentrations. Pirfenidone inhibited, but did not completely prevent, tissue damage in the small intestine, as well as hypotension and oedema, but neutropenia and bradycardia were not significantly changed by treatment. 4. Thus, pirfenidone effectively moderates both local and some systemic effects of ischaemia-reperfusion injury in the rat small intestine model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12366391     DOI: 10.1046/j.1440-1681.2002.03766.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

1.  Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.

Authors:  Atsushi Hirano; Arihiko Kanehiro; Katsuichiro Ono; Wataru Ito; Akio Yoshida; Chiharu Okada; Hiromi Nakashima; Yasushi Tanimoto; Mikio Kataoka; Erwin W Gelfand; Mitsune Tanimoto
Journal:  Am J Respir Cell Mol Biol       Date:  2006-05-04       Impact factor: 6.914

2.  Corrective Effect of Verbascoside on Histomorphological Differences and Oxidative Stress in Colon Mucosa of Rats in Which Colon Ischemia-Reperfusion Injury was Induced.

Authors:  Ayşe Nur Değer; Filiz Özyiğit; Fatma Emel Koçak; Zülfü Bayhan; Sezgin Zeren; Özlem Arık; Hakkı Değer
Journal:  Turk J Gastroenterol       Date:  2021-07       Impact factor: 1.852

Review 3.  Ischemia-reperfusion injury of the intestine and protective strategies against injury.

Authors:  Ismail Hameed Mallick; Wenxuan Yang; Marc C Winslet; Alexander M Seifalian
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 4.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

5.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

6.  Effects of Ukrain on intestinal apoptosis caused by ischemia-reperfusion injury in rats.

Authors:  Raziye Akcılar; Aydın Akcılar; Cengiz Koçak; Fatma Emel Koçak; Zeynep Bayat; Hasan Şimşek; Server Şahin; Bircan Savran
Journal:  Int J Clin Exp Med       Date:  2015-12-15

7.  Function and expression of cystic fibrosis transmembrane conductance regulator after small intestinal transplantation in mice.

Authors:  Penghong Song; Wenfeng Song; Xiaosun Liu; Changhai Jin; Haiyang Xie; Lin Zhou; Biguang Tuo; Shusen Zheng
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  Pirfenidone treatment of idiopathic pulmonary fibrosis.

Authors:  Ye Gan; Erica L Herzog; Richard H Gomer
Journal:  Ther Clin Risk Manag       Date:  2011-02-08       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.